Development of Epigallocatechin and Ascorbic Acid Dual Delivery Transferosomes for Managing Alzheimer’s Disease: In Vitro and in Vivo Studies DOI Creative Commons
Gaurav Mishra, Rajendra Awasthi, Sunil Kumar Mishra

et al.

ACS Omega, Journal Year: 2024, Volume and Issue: 9(33), P. 35463 - 35474

Published: Aug. 7, 2024

Epigallocatechin-3-gallate (EGCG) and ascorbic acid (AA)-loaded transferosomes (TRANS) were developed for brain delivery. The investigation covered EGCG-TRANS, AA-TRANS, EGCG-AA-TRANS formulations using the film hydration technique. We analyzed formed to confirm presence of vesicles loaded with respective drugs their performance within a living organism. sizes particles measured correspondingly at 174.2 ± 1.80, 132.7 12.22, 184.31 9.5 nm. appearance diffused rings in scanning electron microscopic image suggests that payload has crystalline structure. atomic force microscope displayed minimal surface irregularities, potentially indicating lipid layer on surface. Hemolysis results indicated safety vesicles. showed 10.23, 7.21, 8.20% hemolysis EGCG-AA-TRANS, respectively. In case release EGCG was determined be 61.65% 4.61 after 72 h when exposed phosphate buffer saline (pH 7.4). vivo studies show good response against Alzheimer's disease (AD). (82.166%) exhibited higher percentage AChE inhibition comparison EGCG-TRANS (66.550%) AA-TRANS (53.466%). Intranasal delivery resulted approximately 5-fold enhancement memory. Formulation allowed AA accumulate various organs, including brain. suggest could safe effective treating AD.

Language: Английский

Topical transferosomal gel of berberine HCl and diacerein reduced TNF-α and IL-17A levels and reduced epidermal thickness in imiquimod-induced psoriatic BALB/c mice DOI
Siddharth Singh, Rajendra Awasthi

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106731 - 106731

Published: Feb. 1, 2025

Language: Английский

Citations

0
A new era of psoriasis treatment: Drug repurposing through the lens of nanotechnology and machine learning DOI

M Taha Tarek,

Riham I. El-Gogary, Amany O. Kamel

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125385 - 125385

Published: Feb. 1, 2025

Language: Английский

Citations

0
Bone Marrow Delivery of Nilotinib Hydrochloride Through Nanoparticles for Therapy of Chronic Myeloid Leukemia DOI Creative Commons

Bachahalli Madappa Arpitha,

D. Manjula,

K. Vijaya Bhaskar

et al.

BioNanoScience, Journal Year: 2025, Volume and Issue: 15(2)

Published: March 20, 2025

Language: Английский

Citations

0
From Nature to Nanotech: Unlocking Berberine’s Therapeutic Approaches DOI

Shubham Chaudhari,

Manoj Dalabehera,

Rudra Narayan Subudhi

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106924 - 106924

Published: April 1, 2025

Language: Английский

Citations

0
Development of Epigallocatechin and Ascorbic Acid Dual Delivery Transferosomes for Managing Alzheimer’s Disease: In Vitro and in Vivo Studies DOI Creative Commons
Gaurav Mishra, Rajendra Awasthi, Sunil Kumar Mishra

et al.

ACS Omega, Journal Year: 2024, Volume and Issue: 9(33), P. 35463 - 35474

Published: Aug. 7, 2024

Epigallocatechin-3-gallate (EGCG) and ascorbic acid (AA)-loaded transferosomes (TRANS) were developed for brain delivery. The investigation covered EGCG-TRANS, AA-TRANS, EGCG-AA-TRANS formulations using the film hydration technique. We analyzed formed to confirm presence of vesicles loaded with respective drugs their performance within a living organism. sizes particles measured correspondingly at 174.2 ± 1.80, 132.7 12.22, 184.31 9.5 nm. appearance diffused rings in scanning electron microscopic image suggests that payload has crystalline structure. atomic force microscope displayed minimal surface irregularities, potentially indicating lipid layer on surface. Hemolysis results indicated safety vesicles. showed 10.23, 7.21, 8.20% hemolysis EGCG-AA-TRANS, respectively. In case release EGCG was determined be 61.65% 4.61 after 72 h when exposed phosphate buffer saline (pH 7.4). vivo studies show good response against Alzheimer's disease (AD). (82.166%) exhibited higher percentage AChE inhibition comparison EGCG-TRANS (66.550%) AA-TRANS (53.466%). Intranasal delivery resulted approximately 5-fold enhancement memory. Formulation allowed AA accumulate various organs, including brain. suggest could safe effective treating AD.

Language: Английский

Citations

2